RegeneronREGN

NASDAQ · USA · Segment 3 of 8 in the Medicine, pharma & life science value chain: Biotech & innovation

Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.

Biotech & innovation: Innovation-driven biotech companies focused on novel treatment modalities.

Key metrics

Market cap

$82.2B

Price

$828.50

Today

−0.7%

Return YTD

+8.1%

Return 1Y

+39.4%

P/E

19.0

P/S

5.3

P/B

2.6

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

BiotechImmunologyOncology

In the value chain

Products & services

Ophthalmology (Eylea)
Immunology (Dupixent, with Sanofi)
Oncology

Competitors

Risks

Competition on Eylea
Dependence on partner products

Supply chain

← Suppliers

DanaherDHR IlluminaILMN West Pharmaceutical ServicesWST Charles River LaboratoriesCRL

Full supply chain for REGN →

Same segment: Biotech & innovation

AmgenAMGN Gilead SciencesGILD Vertex PharmaceuticalsVRTX BiogenBIIB Alnylam PharmaceuticalsALNY ModernaMRNA IncyteINCY United TherapeuticsUTHR

Compare REGN

REGN vs AMGN REGN vs GILD REGN vs VRTX REGN vs BIIB REGN vs ALNY REGN vs MRNA

See where Regeneron sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →